Natera recently announced that its Signatera minimal residual disease (MRD) test received approval from Japan’s Pharmaceuticals and Medical Devices Agency for use in colorectal cancer patients in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results